Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) received U.S. Food and Drug Administration authorization to begin a registrational Phase 2b study of its SkinJect treatment in patients with Gorlin …
FDA Clears Medicus to Start Gorlin Syndrome Drug Study Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is moving toward activation of a redesigned Phase 2 Teverelix trial after receiving FDA feedback and central ethics approval, cutting planned enrollment …
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) plans to test its Teverelix drug candidate in about 126 patients after receiving FDA feedback and central ethics approval for a redesigned …
Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has asked the U.S. Food and Drug Administration to grant Rare Pediatric Disease Designation for its experimental SkinJect therapy in patients with …
ICYMI: Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has asked the U.S. Food and Drug Administration to grant Rare Pediatric Disease Designation for SkinJect, its experimental treatment for patients with …
Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted an application to health regulators in Abu Dhabi to begin a genomics-based Phase 2a study of its investigational drug Teverelix …
Medicus Seeks UAE Approval for Genomics-Based Endometriosis Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a registrational study protocol to the U.S. Food and Drug Administration for its SkinJect therapy in Gorlin syndrome, a rare …
ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder Read More
PHILADELPHIA, PA — Medicus Pharma (Nasdaq: MDCX) has advanced its SkinJect® treatment into registrational development for Gorlin Syndrome, a rare genetic disorder that causes recurring skin cancers and often requires …
Medicus Pharma Seeks FDA Path for Rare Skin Cancer Disorder Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has secured access to up to $22 million in new financing, providing the biotechnology company with additional capital to fund clinical development …
Medicus Secures $22 Million Financing to Extend Cash Runway Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported expanded Phase 2 data for its SkinJect skin cancer therapy and advanced development of its Teverelix prostate cancer program during the …
Medicus Advances Cancer Pipeline as Losses Widen Read More